Your shopping cart is empty.

IRINOTECANpgx

IRINOTECANpgx
Adequate response to irinotecan treatment
Adequate response to treatment with irinotecan. The DNA test studies the UGT1A1 gene polymorphisms to know whether treatment with irinotecan will have therapeutic efficacy or may have adverse effects on the patient.
152,00

Sample type:

Saliva

Delivery period:

30 - 40 days from sample receipt.
Last update of the document Jun, 10/06/2019 - 13:22

Irinotecan DNA test

This chemotherapeutic drug is generally used for the treatment of advanced colorectal cancer, either alone or in combination with other antineoplastic drugs such as 5-fluorouracil or cetuximab.

This drug is associated with serious and frequent adverse effects, including: vomiting, hyperbilirubinemia, diarrhea, cholinergic syndrome. But the most relevant is neutropenia, which is reversible and non-cumulative. It is very serious and limits the dose of irinotecan that can be used.

Irinotecan is metabolized through CYP3A4 into inactive metabolites and through carboxylesterases into its active metabolite SN-38. Which is metabolized by conjugation with the enzyme UGT1A1. This protein catalyses the transformation of SN-38 by the addition of a molecule of glucuronic acid in order to inactivate the molecule and facilitate its elimination.

The genetic defects in the gene that encodes the UGT1A1 protein cause a lower metabolism of irinotecan. Knowing the genotype of UGT1A1 allows stratifying patients between those who can tolerate irinotecan well without risk of neutropenia and those who have a very low tolerance to irinotecan with a high incidence of neutropenia.

The determination of polymorphism * 28 UGT1A1, which is not functional, mentioned in the prospectus of irinotecan as a marker of risk of adverse effects, as required by the FDA American agency. Irinotecan has been one of the first drugs with a pharmacogenetic marker validated by official agencies.

Interpretation of the report in polytherapy

In this report, the "green" labeling of a certain drug with the patient's genes indicates that it can be prescribed in the standard dose conditions disclosed in the prospectus or those recommended by the physician. This applies in the case of monotherapy.

However, if the patient takes several medications, which is very common, although in the report would appear in "green" can cause adverse effects due to possible interactions between them, which can sometimes be severe, either by toxicity or by therapeutic failure.

Drugs are chemicals that may interfere the normal metabolism of other drugs. Interferences that are also applicable to the chemical substances of various medicinal plants and food supplements.

Consequently, the whole of the medication, together with the consumer products or life habits of the patient, must undergo an evaluation of pharmacological interactions.

Consulting g-Nomic® Pharmacogenetics interpretation software, before prescribing, is an effective aid to avoid most adverse effects or therapeutic failures due to medication.

g-Nomic® interrelates all drugs, herbs, nutritional supplements and lifestyle, with the patient's genes. It also advises the most appropriate dose to prescribe.

This text has been translated automatically using an electronic translator, so the Spanish version should prevail. Please check in case of doubt.

You will receive the sample collection kit. You can request additional kits if you need it.

Sample collection kit content:
You will get a box with sample collection kit. Within the kit you will find:

  1. Saliva collector.
  2. Instructions for the sample collection.
  3. Informed consent sheet and application form.
  4. Security bag to enter the sample for shipment.
  5. Envelope bag.

Process to follow:

  1. Follow the instructions for collecting the sample.
  2. After obtaining the sample, include it in the return envelope, remember to put into the informed consent sheet and the application form.
  3. No shipping costs on Spanish territory.
  4. An email confirmation will be sent when your sample si received.
  5. When the study will be completed you will receive a new e-mail to inform you that your report is already available in "My results".

Info producto mobile

Profile Information

Irinotecan DNA test

This chemotherapeutic drug is generally used for the treatment of advanced colorectal cancer, either alone or in combination with other antineoplastic drugs such as 5-fluorouracil or cetuximab.

This drug is associated with serious and frequent adverse effects, including: vomiting, hyperbilirubinemia, diarrhea, cholinergic syndrome. But the most relevant is neutropenia, which is reversible and non-cumulative. It is very serious and limits the dose of irinotecan that can be used.

Irinotecan is metabolized through CYP3A4 into inactive metabolites and through carboxylesterases into its active metabolite SN-38. Which is metabolized by conjugation with the enzyme UGT1A1. This protein catalyses the transformation of SN-38 by the addition of a molecule of glucuronic acid in order to inactivate the molecule and facilitate its elimination.

The genetic defects in the gene that encodes the UGT1A1 protein cause a lower metabolism of irinotecan. Knowing the genotype of UGT1A1 allows stratifying patients between those who can tolerate irinotecan well without risk of neutropenia and those who have a very low tolerance to irinotecan with a high incidence of neutropenia.

The determination of polymorphism * 28 UGT1A1, which is not functional, mentioned in the prospectus of irinotecan as a marker of risk of adverse effects, as required by the FDA American agency. Irinotecan has been one of the first drugs with a pharmacogenetic marker validated by official agencies.

Interpretation of the report in polytherapy

In this report, the "green" labeling of a certain drug with the patient's genes indicates that it can be prescribed in the standard dose conditions disclosed in the prospectus or those recommended by the physician. This applies in the case of monotherapy.

However, if the patient takes several medications, which is very common, although in the report would appear in "green" can cause adverse effects due to possible interactions between them, which can sometimes be severe, either by toxicity or by therapeutic failure.

Drugs are chemicals that may interfere the normal metabolism of other drugs. Interferences that are also applicable to the chemical substances of various medicinal plants and food supplements.

Consequently, the whole of the medication, together with the consumer products or life habits of the patient, must undergo an evaluation of pharmacological interactions.

Consulting g-Nomic® Pharmacogenetics interpretation software, before prescribing, is an effective aid to avoid most adverse effects or therapeutic failures due to medication.

g-Nomic® interrelates all drugs, herbs, nutritional supplements and lifestyle, with the patient's genes. It also advises the most appropriate dose to prescribe.

This text has been translated automatically using an electronic translator, so the Spanish version should prevail. Please check in case of doubt.

Sample type and process to follow

You will receive the sample collection kit. You can request additional kits if you need it.

Sample collection kit content:
You will get a box with sample collection kit. Within the kit you will find:

  1. Saliva collector.
  2. Instructions for the sample collection.
  3. Informed consent sheet and application form.
  4. Security bag to enter the sample for shipment.
  5. Envelope bag.

Process to follow:

  1. Follow the instructions for collecting the sample.
  2. After obtaining the sample, include it in the return envelope, remember to put into the informed consent sheet and the application form.
  3. No shipping costs on Spanish territory.
  4. An email confirmation will be sent when your sample si received.
  5. When the study will be completed you will receive a new e-mail to inform you that your report is already available in "My results".

Documentación